MorphoSys’ chief scientist hits the exit, triggering R&D reorganization as they shift focus to US in anticipation of looming FDA approval

Just a few days after opening up its new US headquarters on Boston harbor in prep for what they believe is the imminent approval …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mor­phoSys’ chief sci­en­tist hits the ex­it, trig­ger­ing R&D re­or­ga­ni­za­tion as they shift fo­cus to US in an­tic­i­pa­tion of loom­ing FDA ap­proval